These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15932635)

  • 1. Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study.
    Adamashvili I; Minagar A; Gonzalez-Toledo E; Featherston L; Kelley RE
    J Neuroinflammation; 2005 Jun; 2():13. PubMed ID: 15932635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.
    Minagar A; Adamashvili I; Kelley RE; Gonzalez-Toledo E; McLarty J; Smith SJ
    J Neuroinflammation; 2007 Jul; 4():16. PubMed ID: 17601341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble HLA in saliva of patients with autoimmune rheumatic diseases.
    Adamashvili I; Pressly T; Gebel H; Milford E; Wolf R; Mancini M; Sittg K; Ghali GE; Hall V; McDonald JC
    Rheumatol Int; 2002 Jun; 22(2):71-6. PubMed ID: 12070679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
    Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2006 Feb; 12(1):2-12. PubMed ID: 16459714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble HLA in human body fluids.
    Aultman D; Adamashvili I; Yaturu K; Langford M; Gelder F; Gautreaux M; Ghali GE; McDonald J
    Hum Immunol; 1999 Mar; 60(3):239-44. PubMed ID: 10321960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
    Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble HLA class I and class II antigens in patients with multiple sclerosis.
    Ott M; Seidl C; Westhoff U; Stecker K; Seifried E; Fischer PA; Grosse-Wilde H
    Tissue Antigens; 1998 Mar; 51(3):301-4. PubMed ID: 9550332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients.
    Filaci G; Contini P; Brenci S; Gazzola P; Lanza L; Scudeletti M; Indiveri F; Mancardi GL; Puppo F
    Hum Immunol; 1997 Apr; 54(1):54-62. PubMed ID: 9154458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
    Fainardi E; Granieri E; Tola MR; Melchiorri L; Vaghi L; Rizzo R; Castellazzi M; Ceruti S; Paolino E; Baricordi OR
    J Neuroimmunol; 2002 Dec; 133(1-2):151-9. PubMed ID: 12446018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis.
    Rizzo R; Bortolotti D; Fredj NB; Rotola A; Cura F; Castellazzi M; Tamborino C; Seraceni S; Baldi E; Melchiorri L; Tola MR; Granieri E; Baricordi OR; Fainardi E
    Hum Immunol; 2012 Nov; 73(11):1140-6. PubMed ID: 22922127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
    Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
    Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
    Alsahebfosoul F; Zavaran Hosseini A; Salehi R; Etemadifar M; Esmaeil N; Jamshidian A
    Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):298-305. PubMed ID: 26546899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitation of soluble HLA-DR antigens in human serum and other body fluids.
    Hausmann S; Claus R; Buchwald S; Köhler H; Hausmann D; Falk U; Wegener S
    Beitr Infusionsther Transfusionsmed; 1994; 32():281-7. PubMed ID: 9422113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis.
    Fainardi E; Rizzo R; Castellazzi M; Stignani M; Granieri E; Baricordi OR
    Hum Immunol; 2009 Dec; 70(12):981-7. PubMed ID: 19651179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a competitive enzyme-linked immunosorbent assay for measurements of soluble HLA-G protein.
    Rasmussen M; Dahl M; Buus S; Djurisic S; Ohlsson J; Hviid TV
    Tissue Antigens; 2014 Aug; 84(2):206-15. PubMed ID: 24785939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis.
    Amoriello R; Rizzo R; Mariottini A; Bortolotti D; Gentili V; Bonechi E; Aldinucci A; Carnasciali A; Peruzzi B; Repice AM; Massacesi L; Fainardi E; Ballerini C
    Front Neurol; 2022; 13():872396. PubMed ID: 35693002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.